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Abstract
Background: Flexible, fibreoptic bronchoscopy (FFB) and bronchoalveolar lavage (BAL) have been used for
diagnostic purposes in critically ill ventilated patients. The additional diagnostic value compared to tracheal
aspirations in ventilator-associated pneumonia (VAP) has been questioned. Nevertheless, BAL can provide extra
information for the differential diagnosis of respiratory disease and good antibiotic stewardship. These benefits
should outweigh potential hazards caused by the invasiveness of this diagnostic technique. The focus of the
present study was on the clinical course and complications of patients following BAL procedures up to 24 h.
Methods: Hundred sixty-four FFB guided BAL procedures for suspected pneumonia were analysed in an
observational study. The clinical course of patients was monitored by respiratory and haemodynamic data before
BAL, 1 and 24 h after BAL. Complications were defined and registered. Factors associated with complications were
analysed by logistic regression.
Results: Clinical course: a decrease in average pO2/FiO2 ratio 1 h after BAL from 29 kPa (218 mmHg) to 25 kPa
(189 mmHg) (p < 0.05) was observed which fully recovered within 24 h. Respiratory complications: the incidence of
procedure related hypo-oxygenation (SaO2 ≤ 88 %) and/or bronchospasm was 9 %; a decrease of >25 % PaO2/FiO2
ratio 1 h after BAL was found in 29 % of patients; no bleeding or pneumothorax were registered. Haemodynamic
complications: there were no cases of hypertension and cardiac rhythm disturbances; haemodynamic instability
within the first 24 h after BAL was recorded in 22 %; this was correlated with a cardiovascular diagnosis at
admission (OR 2.9; 95 % CI 1.2 - 6.7) and the presence of cardiovascular co-morbidity (OR 3.5; 95 % CI 1.5 – 8.3). The
incidence of bacteraemia was 7 %. There was no case of procedure related death.
Discussion: Frequently occurring haemodynamic and respiratory instability but no cases of cardiac rhythm
disturbances, bleeding, pneumothorax or procedure related death were attributable to diagnostic FFB and BAL.
The procedures should be conducted under careful supervision by experienced physicians. Only a randomized
controlled trial that compares diagnostic FFB and BAL with a non-invasive strategy could ultimately establish the
safety profile and clinical utility of these procedures in critically ill ventilated patients.
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Summary at a glance: Benefits of bronchoalveolar lavage should outweigh
potential hazards caused by the invasiveness of this diagnostic technique.
The present study is the largest investigation on periprocedural
complications and clinical course.
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Background
Flexible, fibreoptic bronchoscopy (FFB) and bronchoal-
veolar lavage (BAL) have been established for diagnostic
purposes in critically ill ventilated patients in intensive
care units (ICUs). The technique is applicable at the
bedside and therefore makes potentially hazardous pa-
tient transfers outside the ICU unnecessary. With regard
to the diagnosis of ventilator-associated pneumonia
(VAP) there is no consensus in the literature and be-
tween clinicians. Bronchoscopic BAL from the presumed
site of infection with cytological analysis and quantitative
microbiological culture of the lavage fluid is thought by
many to be a specific diagnostic approach to identify pa-
tients with a true infection of the lungs and to enable
tailored antibiotic therapy. The most cited benefit of
BAL is the prevention of incorrect use of antibiotics.
The administration of unnecessary antibiotics is associ-
ated with risks of toxicity and development of multi-
resistance [1–3]. Others question the use of BAL be-
cause several investigations have shown similar outcome
and overall use of antibiotics when clinical diagnostic
criteria added by non-quantitative culture results from
tracheal aspirations were used in the diagnosis of VAP
[4, 5]. However, there are other benefits associated with
the performance of BALs. Direct visualisation of the air-
way by FFB delivers additional clinical information and
guides the selection of lung areas where specimens are
taken [6, 7]. Moreover, the information provided by BAL
analysis is more comprehensive than from tracheal aspi-
rates as it not only can benefit the diagnosis of bacterial
VAP [8] but can also support the diagnosis of alternative
infectious causes [9] or other respiratory diseases [10].
In order to evaluate FFB and BAL as a diagnostic tool
in ICU patients, it is necessary to balance benefits with
potential hazards caused by the invasiveness of the tech-
nique. The focus of the present study is on the clinical
tolerance of FFB and BAL. The clinical course and com-
plications of critically ill mechanically ventilated patients
after a diagnostic FFB and BAL were investigated. Clin-
ical data were collected before BAL, 1 and 24 h after
BAL. The frequency of haemodynamic, respiratory and
procedure related complications were registered. This
information can contribute to the discussion whether or
not utility and benefits of the more invasive diagnostic
approach outweigh its potential risks.
Methods
The study was conducted in the Maastricht University
Medical Centre+, a tertiary-care, university hospital in
the Netherlands with 1,700 ICU admissions per year.
Adult critically ill, mechanically ventilated patients with
a clinical suspicion of infectious pneumonia who under-
went a diagnostic FFB and BAL were included in the
analysis. Exclusion criteria for the procedure were
thrombocytopenia (<40,000/μL) and other coagulation
abnormalities. Only clinical data were used in the study.
The data were collected retrospectively in 43 cases and
prospectively in 121 cases in the period from 2011 to
2014. Patients consented to the use of clinical data for
scientific analysis according to the admission regulations
of the hospital if they did not opt out. This is approved
by the local ethics commission (Medisch Ethische Toet-
singscommissie azM).
Senior registrars or consultant pulmonologists con-
ducted all BAL procedures. The fraction of inspired oxy-
gen (FiO2) was increased to 1.0 for 5 to 15 min prior to
and during FFB and BAL procedures. Patients were anaes-
thetised by an experienced intensive care physician,
present during the whole procedure, with either propofol
or midazolam and fentanyl continuous infusion and as re-
quired rocuronium for muscle relaxation. Patients had tra-
cheal tubes with an inner diameter varying from 7.5 to
8.5 mm or a Portex® tracheal cannula with an inner diam-
eter of 8 mm in place. A flexible, fibreoptic bronchoscope
(Pentax® FB-15H/FB-15X, Pentax Medicals, Tokyo, Japan)
with a calibre of 4.9 mm was introduced and ‘wedged’ into
the affected segmental or subsegmental bronchus. Before
performing BAL, a quick inspection of all the major air-
ways in both lungs was carried out. Sterile saline (0.9 %
sodium chloride at room temperature) was instilled. An
initial aliquot of 20 mL and subsequent four aliquots of
50 mL were immediately aspirated and recovered. After
completing the BAL, the bronchoscope was removed, and
the patient was monitored closely by continuous pulse ox-
imetry and arterial blood gases while the FiO2 was then
gradually decreased. BAL samples were transported to the
laboratory within 15 min after collection and processed
immediately upon arrival. Information about the quality of
BAL sampling was collected. The BAL fluid was regarded
non-representative if the volume of recovery was <20 mL,
the total cell count was < 60.000/mL, the presence of
squamous epithelial cells was >1 %, the presence of bron-
chial epithelial cells was >5 % or in the presence of exten-
sive amounts of debris and damaged cells. Further BAL
workup in the laboratory included: a differential cell
count, microscopic investigation of a Gram-stained prep-
aration, quantitative bacterial and fungal culture. BAL
fluid analysis was considered to support the diagnosis of
VAP when Memphis Consensus Conference criteria were
met. These criteria include: ≥2 % BAL fluid cells contain-
ing intracellular organisms, and/or identification of a
bacterial micro-organism in the BAL fluid in a concentra-
tion of ≥ 104 colony forming units/ml (cfu/mL) [11, 12].
Demographic characteristics and Acute Physiology and
Chronic Health Evaluation (APACHE-II) scores were
recorded on admission. All diagnoses apart from the prin-
cipal reason for admission to the ICU were regarded as
co-morbidities: 1. cardiovascular: severe ischemic heart
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disease, NYHA IV heart failure, disabling peripheral vas-
cular disease; 2. respiratory: disabling chronic pulmonary
disease, COPD Gold III and IV, continuous additional
oxygen therapy; 3. chronic renal failure: chronic dialysis,
serum creatinine level chronically > 177 μmol/L; 4. im-
munocompromised: disease and drug effects, prednisone
equivalent > 7.5 mg/day; 5. active malignancy; 6. neuro-
logic impairment: cerebral haemorrhage, meningitis, en-
cephalitis, severe paresis; 7. chronic coagulation disorder;
8. chronic hepatic failure: hepatic encephalopathy, Child C
cirrhosis, portal hypertension. Patients were classified as
“severe sepsis” following the Surviving Sepsis Campaign
criteria [13]. Clinical parameters were collected at base-
line, at 1 h and 24 h after the BAL procedure. Blood cul-
tures were obtained before and 24 h after the procedure,
chest X-rays were performed within 24 h after BAL and
sputum cultures were taken prior to the procedure. In
general, the results of Gram staining, differential cell
count and percentage of intracellular organisms of sam-
ples obtained by BAL were available within 2 h after bron-
choscopy, preliminary culture results after 1 day, and
definite culture results after 4 days. When BAL fluid ana-
lysis rejected the diagnosis of bacterial pneumonia,
additional steps followed to determine an alternative diag-
nosis. Empirical antibiotic therapy was directed towards
pathogens isolated from clinical and surveillance cultures
of sputum cultures, and patients with VAP were treated
with antibiotics for 8 to 14 days according to causative mi-
croorganisms. In case of clinical suspicion of pneumonia,
antibiotic therapy was initiated after BAL had been per-
formed. When a patient was receiving antibiotics for more
than 48 h for another unrelated infection or for prophy-
laxis on the day that the criteria for a clinical suspicion of
pneumonia were met, antibiotics were not changed until
the BAL procedure.
The clinical course of the patients was monitored for
24 h after diagnostic FFB and BAL. PaO2/FiO2 ratios,
positive end-expiratory pressure (PEEP) levels, fractions of
oxygen (FiO2), ph, PaCo2, mean arterial pressure (MAP),
heart rate and dosages of norepinephrine and dobutamine
were assessed. Clinical complications of BAL were defined
as complications occurring during the BAL procedure and
up to 24 h after BAL. 1. Respiratory complications: hypo-
oxygenation (SaO2 ≤ 88 %) during BAL and/or broncho-
spasm; a decrease in PaO2/FiO2 ratio >25 % compared to
baseline; bleeding defined as haemoptysis requiring med-
ical intervention and/or interruption of the procedure;
pneumothorax. 2. Haemodynamic complications: hyper-
tension defined as an increase of MAP >25 % baseline;
cardiac rhythm disturbances defined as newly developed
pathologic rhythm (atrial fibrillation, ventricular tachy-
cardia, ventricular fibrillation, asystole) or bradycardia
or rapid atrial fibrillation with decrease in MAP;
haemodynamic instability defined as a decrease of
MAP < 55 mmHg at any time and/or necessity to initi-
ate norepinephrine > 0.15 μg/kg/min or dubutamine
>5 μg/kg/min and/or the necessity to more than double
the dose of norepinephrine or dobutamine. 3. Bacter-
aemia: positive blood cultures following BAL. 4. Death:
procedure related death within 24 h. Possible correlations
of demographic and clinical items (age, gender, APACHE
II, SOFA, diagnosis at admission, severe sepsis, co-
morbidities) with a respiratory and hemodynamic compli-
cation following BAL were analysed by multiple logistic
regression. Odds ratios with 95 % confidence interval were
calculated.
Data were analysed using the SPSS version 20 statis-
tical package for MS Windows. Quantitative variables
were expressed as means with standard deviations (SD).
Qualitative variables were reported with the percentage
distribution of each of the categories. Fisher’s Exact Test
and Chi Square Test were used for the analyses of cat-
egorical variables and ANOVA analysis and Kruskal-
Wallis test for numerical variables. Linear mixed models
analysis was performed in all patients, excluding con-
secutive BALs in the same patients who underwent
more than one BAL.
Results
A total of 164 datasets of FFB and BAL procedures were
recorded during the study period.
Patient demographics are shown in Table 1. In 68
patients (41 %) analysis of BAL fluid supported the diag-
nosis bacterial pneumonia. The most frequently acquired
micro-organisms were Pseudomonas aeruginosa (12),
Staphylococcus aureus (5) and Escherichia coli (5). In
retrospection 92 % of all BAL positive patients received
adequate empiric antibiotic treatment. Ninety-six BAL
fluid analyses were classified as negative. However, in 68 %
of these an alternative diagnosis could be established in
the following diagnostic process [Table 2]. In 26 patients
there was a significant presence of viruses in the BAL
fluid. In seven patients Pneumocystis jiroveci could be de-
tected. Further diagnostic workup including computed
tomography, lung biopsy, ultrasound examinations and
advanced laboratory tests revealed a broad spectrum of al-
ternative diagnoses in the putative ventilator-associated
pneumonia patient not meeting lavage-based diagnostic
criteria.
The clinical course of patients following diagnostic FFB
and BAL is illustrated in Table 3. Baseline data before
BAL were compared with data after 1 h and 24 h. The
average PaO2/FiO2 ratio declined from 29 kPa
(218 mmHg) to 25 kPa (189 mmHg) (p < 0.05) after 1 h
but had reached baseline again after 24 h. The average
PEEP level of 9.4 cmH2O was not significantly in-
creased after 1 h and kept constant after 24 h. After
1 h, PEEP level was increased in 7 % of patients and in
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15 % after 24 h. The average FiO2 level of 52 % was not
significantly altered after 1 h and had decreased to
43 % (p < 0.0001) 24 h after BAL. One hour after BAL,
27 % of patients had an increased FiO2 of ≥ 10 % com-
pared to baseline; after 24 h 8 % of patients had an in-
creased FiO2 of ≥ 10 % compared to baseline. The pH
and paCO2 were unchanged after 1 and 24 h compared
to baseline. The averages of haemodynamic parameters
(MAP, heart rate, number of patients receiving norepin-
ephrine and/or dobutamine and dose) were not signifi-
cantly different after 1 and 24 h from baseline.
The following complications of diagnostic FFB and
BAL were registered. 1. Respiratory complications:
hypo-oxygenation (SaO2 ≤ 88 %) during BAL and/or
bronchospasm was documented in 9 % of patients; a
decrease of >25 % PaO2/FiO2 ratio compared to base-
line was registered in 29 % of patients 1 h after BAL; in
half of these patients a persisting decrease of >25 %
PaO2/FiO2 ratio was found 24 h after BAL; no cases of
clinically significant bleeding requiring interruption of
the procedure or treatment were reported. Further ana-
lysis could not establish a significant correlation of re-
spiratory complications with demographic or clinic
items [Fig. 1]. 2. Haemodynamic complications: no pa-
tients had hypertension or cardiac rhythm disturbances
during the FFB and BAL procedure; hemodynamic in-
stability (as defined in the methods section) was found
Table 1 Patient demographics
Age (years) 61 ±14
Gender male 116 71 %
female 48 29 %
APACHE II 21 ±9
SOFA (at time of BAL) 7 ±4
Parameters
(at time of BAL)
pH <7.25 10 6 %
PaCO2≥ 7.5kPa (56 mmHg) 9 5 %






respiratory 64 38 %
cardiovascular 37 22 %
haematological 19 11 %
gastrointestinal 16 10 %
trauma/orthopaedic 10 6 %
neurological 12 7 %
urogenital 3 2 %




Co-morbidity none 53 33 %
one item 72 44 %
two items 35 21 %
≥ three items 4 2 %
Co-morbidity cardiovascular 34 21 %
respiratory 12 7 %
chronic renal failure 8 5 %
immunocompromised 47 29 %
active malignancy 32 20 %
neurologic impairment 17 10 %
coagulation disorder 3 2 %
chronic hepatic failure 2 1 %
BAL positive 68 41 %
ICU mortality 80 49 %
In-hospital mortality 90 55 %
Cause of death cardiovascular 13 15 %
persistent respiratory failure 24 27 %
neurological impairment 9 10 %
multi organ failure 10 11 %
active malignancy 28 31 %
other 4 4 %
unknown 2 2 %
Results are given either as number, percentages or mean ± standard deviation
Table 2 Alternative diagnosis in patients with negative bacterial
growth BAL result





Bronchiolitis obliterans organizing pneumonia 3
Usual interstitial pneumonia 1
All trans retinoic acid (ATRA) syndrome 1
Pulmonary embolism; obstructive shock 2
Endocarditis 1
Abdominal sepsis with ARDS 4
Necrotizing pancreatitis 2
Abdominal ischaemia 1
Urinary tract sepsis with ARDS 2
Ovarian cancer with pulmonary metastases 1
Systemic lupus erythematosus 1
Toxic epidermal necrolysis 1
Postanoxic encephalopathy with multiple infarction 1
Myasthenia gravis 1
None established 31
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in 5 % of patients 1 h after BAL and 7 % of patients
24 h after BAL. However, 22 % of patients had
hemodynamic instability at any time during the first
24 h after BAL. This was correlated with a cardiovascu-
lar diagnosis at admission (OR 2.9; 95 % CI 1.2 - 6.7)
and the presence of cardiovascular co-morbidity (OR
3.5; 95 % CI 1.5 - 8.3) [Fig. 2]. Multiple logistic regres-
sion revealed that the correlation was independent
from age and gender (OR 2.3; 95 % CI 1 – 5.6 / OR 2.8;
95 % CI 1.1 – 6.7) and the APACHE II score at admis-
sion (OR 3.5; 95 % CI 1.5 – 8.5 / OR 3.5; 95 % CI 1.4 –
8.6) 3. Bacteraemia: newly positive blood cultures were
observed in 7 % of patients. 4. Death: no case of pro-
cedure related death was reported.
Discussion
The present observational study monitored the 24 h
clinical course and complications following diagnostic
FFB and BAL in critically ill ventilated patients. Patients’
characteristics illustrate the severity of illness before
BAL procedures. The high percentage of patients with
active malignancy, immunosuppression and neurologic
impairment can be explained by the function of the hos-
pital as referral centre for haematology, oncology, im-
munologic diseases and neurosurgery.
Following diagnostic FFB and BAL there were no cases
of cardiac rhythm disturbances, bleeding, pneumothorax
or procedure related death during this study. Nevertheless,
haemodynamic (22 %) and respiratory (29 %) instability







PaO2/FiO2 [kPa] 29 (CI 25–32) 25 (CI 23–29) p < 0.05 31 (CI 27–33)
PaO2/FiO2 [mmHg] 218 (CI 188–240) 189 (CI 173–218) 233 (CI 203–248)
PaO2/FiO2 decreased >25 %
baseline [% of patients]
29 % 14 %
PEEP mean [cmH2O] 9.4 (CI 9.1–9.8) 9.6 (CI 9.2–9.9) 9.6 (CI 9.2–10)
PEEP increased 7 % 15 %
FiO2 mean [%] 52 (CI 49–55) 54 (CI 51–57) 43 (CI 41–46) p < 0.0001
FiO2 increased≥ 10 % baseline
[% of patients]
27 % 8 %
pH mean 7.41 (CI 7.40–7.42) 7.40 (CI 7.39–7.41) 7.41 (CI 7.40–7.42)
pCO2 mean [kPa] 5.2 (CI 5.0–5.4) 5.4 (CI 5.2–5.6) 5.2 (CI 5.0–5.4)
pCO2 mean [mmHg] 39 (CI 38–41) 41 (CI 39–42) 39 (CI 38–41)
MAP mean [mmHg] 84 (CI 81–86) 79 (CI 76–81) 83 (CI 81–86)
Heart rate mean
[beats/min]
96 (CI 93–100) 94 (CI 93–99) 91 (CI 88–94)
Norepinephrine
[% of patients]
58 % 57 % 62 %




Dobutamine [% of patients] 3 % 3 % 3 %






5 % 7 %
Hemodynamic
instabilitya at any
time within 24 h
[% of patients]
22 %
CI 95 % confidence interval, MAP mean arterial pressure, PEEP positive
end-expiratory pressure, FiO2 fraction of inspired oxygen, PaO2 arterial partial oxygen pressure, SOFA sequential organ failure assessment
adecrease of mean arterial pressure (MAP) < 55 mmHg and/or necessity to initiate norepinephrine > 0.15 μg/kg/min / dubutamine >5 μg/kg/min and/or the
necessity to more than double the dose of norepinephrine or dobutamine
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according to the applied definitions were frequently re-
corded. Due to the complexity of human nature, physi-
ology and pathophysiologic mechanisms of diseases,
there might be no simple and consistent definition of
respiratory and haemodynamic instability. It has been
notoriously difficult to define cut-off variables with re-
gard to vital parameters in clinical trials and practice
[14–16]. A single vital parameter or even a set of abso-
lute values of vital parameters will rarely suffice. For
example in patients with preserved or abolished
Fig. 1 Results – Odds ratios and 95 % confidence interval for respiratory complications1 of BAL. 1 Decrease of the PaO2/FiO2 > 25 % compared to
baseline within 1 h after BAL
Fig. 2 Results – Odds ratios with 95 % confidence interval for hemodynamic complications 1 of BAL. A cardiovascular diagnosis upon admission
and cardiovascular co-morbidity are associated with significantly more hemodynamic complications. 1Decrease of mean arterial pressure (MAP)
< 55 mmHg at any time and/or necessity to initiate norepinephrine > 0.15 μg/kg/min / dubutamine >5 μg/kg/min and/or the necessity to
more than double the dose of norepinephrine or dobutamine
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autoregulation the same absolute value of MAP can
have different effects on the blood flow and vital func-
tions. Hemodynamic and respiratory variables in
critical care and ventilated patients markedly interact.
MAP and heart rate should be related to dosages of
inotropic and vasoactive medication; partial pressure of
oxygen should always be correlated with the applied
fraction of oxygen and PEEP level. Relative changes of
vital parameters with regard to baseline might provide
a better assessment of the impact of invasive diagnostic
techniques. The definitions for respiratory and
hemodynamic complications in the present study were
eventually based on pathophysiologic reasoning, earlier
publications of bronchoscopy associated complications
[17, 18] and literature [19]. Haemodynamic instability
in the study population was associated with a cardio-
vascular diagnosis at admission or presence of cardio-
vascular co-morbidity reflecting an expected causal
relationship. Interestingly these two risk factors were
independent from age, gender and APACHE II score.
Haemodynamic changes could have been influenced by
cardiovascular effects of the applied anaesthetic drugs
to facilitate the procedure, as judged by the supervising
physician. Hypo-oxygenation (SaO2 ≤ 88 %) during BAL
and/or bronchospasm occurred in 9 % of patients and
was always manageable and did not necessitate termin-
ating the procedure. Nevertheless, 1 h after BAL there
was a significant decrease in the average PaO2/FiO2 ratio
which fully recovered to baseline after 24 h. Average PEEP
and FiO2 levels remained constant. After 24 h more pa-
tients had PEEP adjustment than 1 h after BAL explaining
the decrease of the average FiO2 from 52 to 43 %.
Altogether, haemodynamic and respiratory instability
could be attributed to FFB and BAL in a substantial
number of patients. This is in line with previous studies
concerning the safety of bronchoscopic diagnostic tech-
niques in critical care patients. Table 4 provides an over-
view of the literature [17, 18, 20–25]. The studies differ
in patient population, setting, applied diagnostic tech-
nique and length of observation. All authors described a
certain impact of diagnostic FFB on respiratory mechan-
ics, respiratory and hemodynamic parameters.
To warrant a high procedural safety level of FFB and
BAL in ICU patients, a structured approach is
mandatory [6]. An experienced bronchoscopist should
concentrate on the procedure while another physician
surveys the patient, regulates analgosedation and adjusts
the support of vital functions as necessary. The benefits
of a BAL should be weighed against the potential
additional harm for the patient secondary to the inva-
siveness of the procedure and the additional costs as
compared to less invasive diagnostic measures. There is
ongoing discussion on the pros and cons of BAL in the
diagnosis of VAP. In this study, the majority of patients
had a substantial benefit from the BAL. In 41 % of
patients the diagnosis of bacterial pneumonia was con-
firmed by BAL fluid analysis. In a further 24 % of pa-
tients a viral or fungal infection or Pneumocystis jiroveci
pneumonia could be diagnosed. When no infectious
cause in the BAL fluid analysis was detected, the medical
team was urged to look for non-infectious diagnoses
without any delay and to adjust the therapy. This prac-
tice could beneficially affect the patients’ outcome and
at the same time reduce unnecessary antibiotic use. The
Table 4 Results of studies with regard to bronchoscopically guided diagnostic techniques in ICU patients
Reference Year Patients Setting Results
Trouillet
et al. [20]
1990 N = 107 acutely ill ventilated
patients; bronchial brush
26 % of patients (p < 0.01) with a drop in PaO2; modest alterations in mean systolic




1993 N = 30 mechanically ventilated
patients; BAL
mild haemodynamic variations but a marked decrease in PaO2 during bronchoscopy




1993 N = 110 ARDS patients; BAL 21 patients with a moderate to severe drop in PaO2/FiO2; four patients with a decrease
of mean arterial pressure < 60 mmHg; six patients developed arrhythmias during the
procedure; one pneumothorax; two cases of bacteraemia within 24 h
Turner
et al. [25]
1994 N = 107 intensive care patients;
bronchial brush
study describes therapeutic and diagnostic fiberoptic bronchoscopies; 23 bronchial




2001 N = 37 mechanically ventilated
patients; BAL
patients showed a lower PaO2/FiO2 ratio and higher MAP after BAL up to 24 h
Chou
et al. [23]
2009 N = 56 mechanically ventilated
patients; BAL
alterations in respiratory mechanics more pronounced by BAL in patients with intrinsic
positive end-expiratory pressure before the procedure was started
Estella [24] 2010 N = 50 Mechanically ventilated
patients; BAL
respiratory mechanics during BAL procedures showed significant decrease in lung
compliance and increase in resistance that only reached baseline after 90 min to 3 h
Estella [18] 2012 N = 148 ICU patients; BAL desaturations <90 % (7 %), supraventricular tachycardia (4 %) and slight bronchial
bleeding (2 %)
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latter becomes increasingly important with the rapid
emergence and dissemination of multi-drug resistant mi-
croorganisms particularly in the ICU environment
worldwide [26]. Antibiotic stewardship programs (ASPs)
were developed to address the problem and ensure a re-
sponsible use of antimicrobial drugs [27, 28]. The diag-
nostic BAL can be implemented in an ASP and deliver
important information to confirm an infectious disease,
to optimize antimicrobial treatment (e.g. in the presence
of Pneumocystis jiroveci), to de-escalate and narrow anti-
biotic therapy once the responsible pathogen is known
and to stop antibiotic therapy in patients unlikely to
have infections [27, 29].
Limitations of the study are its observational design of
FFB and BAL as standard of care in a single centre with-
out a randomized control group. Part of the included cases
were retrospectively collected. In the assessment of a long
term clinical course it might be difficult to differentiate
the natural course of the underlying disease from the im-
pact of the bronchoscopic intervention. Evidently, FFB
and BAL procedures should not be performed in patients
in a deplorable clinical condition. Unfortunately, the
present study does not allow to define clear-cut clinical
criteria for withholding FFB and BAL because the limited
number of patients with severe acidosis (pH < 7.25; n =
10), hypercapnia (PaCo2 ≥ 7.5kPa/56 mmHg; n = 9) and
hypoxia (PaO2 ≤ 8kPa/60 mmHg; n = 10 or PaO2/FiO2 ra-
tio ≤13kPa/100 mmHg; n = 12). Further limitation is the
lack of the measurement of respiratory mechanics before,
during and after FFB.
Conclusion
Frequently occurring haemodynamic and respiratory in-
stability could be attributable to diagnostic FFB and BAL
but no cases of cardiac rhythm disturbances, bleeding,
pneumothorax or procedure related death were observed
in the present study. The procedures should be con-
ducted under careful supervision by experienced physi-
cians. Only a randomized controlled trial that compares
diagnostic FFB and BAL with a non-invasive strategy
could ultimately establish the safety profile and clinical
utility of these procedures in critically ill ventilated
patients.
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